| Followers | 4045 |
| Posts | 152978 |
| Boards Moderated | 3 |
| Alias Born | 08/05/2009 |
Friday, May 24, 2024 9:13:40 AM
For those who are curious why $VSTM is down 60% on premarket, being 50% yesterday afterhours, despite positive RAMP 205 data (High ORR)
$VSTM 12 patients experienced treatment emergent serious adverse events, 11 patients with grade ≥3 pic.twitter.com/pY34tS6maD
— Swat (@SwatOptions) May 24, 2024
For those who are curious why $VSTM is down 60% on premarket, being 50% yesterday afterhours, despite positive RAMP 205 data (High ORR)❓
— Dogtor🎰📈 (@Dogtor01416800) May 24, 2024
Today Company announce that they will submit BLA for combo treatment only for a mutant subgroup, which significantly reduces the TAM
👀 $XBI https://t.co/Au1lEsh0qU pic.twitter.com/LzSvNS1T7n
Recent VSTM News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/29/2026 08:40:39 PM
- Verastem Oncology to Present at Jefferies Healthcare Conference • Business Wire • 05/27/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 10:23:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 10:22:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 10:19:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 10:18:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 10:12:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 12:15:11 PM
- Verastem Oncology Appoints Michael P. Bailey to its Board of Directors • Business Wire • 05/26/2026 11:30:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:21:41 PM
- Verastem Oncology to Present at Upcoming Investor Conferences • Business Wire • 05/12/2026 11:30:00 AM
- On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer • Business Wire • 05/08/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:11:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:07:25 PM
- Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates • Business Wire • 05/07/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2026 08:01:09 PM
- Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer • Business Wire • 04/30/2026 11:30:00 AM
- Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 • Business Wire • 04/23/2026 11:30:00 AM
- Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers • Business Wire • 04/10/2026 11:00:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/09/2026 08:14:51 PM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2026 09:20:14 PM
- Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 • Business Wire • 03/17/2026 10:03:00 PM
- Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers • Business Wire • 03/17/2026 08:44:00 PM

